Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Cancer × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 128 Lung Neoplasms 58 Carcinoma, Hepatocellular 53 Small Cell Lung Carcinoma 43 Breast Neoplasms 39 Squamous Cell Carcinoma of Head and Neck 30 Urinary Bladder Neoplasms 28 Colorectal Neoplasms 25 Cholangiocarcinoma 24 Biliary Tract Neoplasms 24 Neoplasms 22 Triple Negative Breast Neoplasms 21 Ovarian Neoplasms 21 Pancreatic Neoplasms 20 Neoplasm Metastasis 19 Head and Neck Neoplasms 16 Melanoma 14 Liver Neoplasms 14 Carcinoma, Renal Cell 13 Recurrence 12 Prostatic Neoplasms 12 Carcinoma 12 Esophageal Neoplasms 11 Uterine Cervical Neoplasms 10 Stomach Neoplasms 10 Endometrial Neoplasms 10 Carcinoma, Transitional Cell 10 Gallbladder Neoplasms 8 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Squamous Cell 7

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 fludarabine 1 durvalumab 1 cabazitaxel 1 XRP6258 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cyclophosphamide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡